Sign In
Buy MIST
$1.28
+0 (+0%)
At Close: Jul 13, 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:30pm, Thursday, 02'nd Jul 2026
MONTREAL and CHARLOTTE, N. C. , July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards,
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:30pm, Thursday, 02'nd Jul 2026
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity aw
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
09:00am, Tuesday, 23'rd Jun 2026
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
01:32pm, Wednesday, 10'th Jun 2026
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
Milestone Pharmaceuticals: Here Comes The Revenue Ramp
03:38pm, Tuesday, 09'th Jun 2026
Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage,
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
08:30am, Thursday, 14'th May 2026
MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova
Why Milestone Pharmaceuticals Stock Wilted on Wednesday
05:56pm, Wednesday, 13'th May 2026
The biotech fell well short of analyst projections in the first quarter.
Milestone Pharmaceuticals Q1 Earnings Call Highlights
02:11pm, Wednesday, 13'th May 2026
Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventric
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
01:20pm, Wednesday, 13'th May 2026
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
10:04am, Wednesday, 13'th May 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported first-quarter earnings on Wednesday before the market opened. Here's a rundown of the report.
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
09:20am, Wednesday, 13'th May 2026
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
07:11am, Wednesday, 13'th May 2026
MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovativ
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
08:00am, Wednesday, 06'th May 2026
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative ca
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts
02:12am, Friday, 24'th Apr 2026
Shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the company, Market
Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Associ
